A research study to find out if the study treatment alpelisib (BYL719) is safe and can help others who have confirmed diagnosis of PIK3CA-related overgrowth spectrum (PROS)

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2025
This article has no abstract
Epistemonikos ID: e98984ee82c52fb8d40f947afe90f9e1c4db8256
First added on: Jan 16, 2026